Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics

Gut

Volumn 47, Issue 4, 2000, Pages 487-496

  Vasiliauskas, E A ^a   Kam, L Y ^a   Karp, L C ^a   Gaiennie, J ^a   Yang, H ^a   Targan, S R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti Saccharomyces cerevisiae antibody; Antineutrophil cytoplasmic antibody; Crohn's disease; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

BIOCHEMICAL MARKER; FUNGUS ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; PERINUCLEAR ANTINEUTROPHIL CYTOPLASMIC ANTIBODY; SACCHAROMYCES CEREVISIAE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CLINICAL FEATURE; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; ONSET AGE; PRIORITY JOURNAL; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, FUNGAL; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; CROHN DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; REGRESSION ANALYSIS; SACCHAROMYCES CEREVISIAE;

EID: 0033805362     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.47.4.487     Document Type: Article

References (67)

1. 1 Crohn BB, Ginzburg L, Oppenheimer GD. Regional Ileitis. JAMA 1932;99:1323-9.
2. 2 Targan S, Murphy LK. Serologic and mucosal markers of ulcerative colitis and Crohn's disease: implications of pathophysiology for diagnosis. In: Scholmerich J, Kruis W, Goebell H, et al, eds. Inflammatory bowel diseases -pathophysiology as basis of treatment. Dordrecht: Kluwer Academic Publishers, 1993:283-6.
3. 3 Rotter JI, Yang H. Delineating the major aetiological risk factors for IBD: the genetic susceptibilities. In: Scholmerich J, Kruis W, Goebell H, et al, eds. Inflammatory bowel diseases - pathophysiology as basis of treatment. Dordrecht: Kluwer Academic Publishers, 1993:9-18.
4. 4 Satsangi J, Jewell DP, Rosenberg WMC, et al. Genetics of inflammatory bowel disease. Gut 1994;35:696-700.
5. 5 Yang H, Rotter JI. The genetics of inflammatory bowel disease: genetic predispositions, disease markers, and genetic heterogeneity. In: Targan SR, Shanahan F, eds. Inflammatory bowel disease: from bench to bedside. Baltimore: Williams and Wilkins, 1994:32-64.
6. 6 Vasiliauskas EA, Plevy SE, Landers CJ, et al. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology 1996;110:1810-19.
7. 7 Targan SR, Landers CJ, Cobb L, et al. Perinuclear anti-neutrophil cytoplasmic antibodies are spontaneously produced by mucosal B cells of ulcerative colitis patients. J Immunol 1995;155:3262-7.
8. 8 Sandborn WJ, Landers CJ, Tremaine WJ, et al. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc 1996;71:431-6.
9. 9 Vecchi M, Bianchi MB, Sinico RA, et al. Antibodies to neutrophil cytoplasm in Italian patients with ulcerative colitis: sensitivity, specificity and recognition of putative antigens. Digestion 1994;55:34-9.
10. 10 Vecchi M, Bianchi MB, Calabresi G, et al. Long-term observation of the perinuclear anti-cytoplasmic antibody status in ulcerative colitis patients. Scand J Gastroenterol 1998;33: 170-3.
11. 11 Boerr LA, Sambuelli AM, Katz S, et al. Clinical heterogeneity of ulcerative colitis in relation to frequency of pANCA reactivity. Gastroenterology 1995;108:A785.
12. 12 Vecchi M, Gionchetti P, Bianchi MB, et al. p-ANCA and development of pouchitis in ulcerative colitis patients after proctocolectomy and ileoanal pouch anastomosis. Lancet 1994;344:886-7.
13. 13 Patel RT, Stokes R, Birch C, et al. Influence of total colectomy on serum antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Br J Surg 1994;81:724-6.
14. 14 Sandborn WJ, Landers CJ, Tremaine WJ, et al. Antineutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal pouch-anal anastomosis. Am J Gastroenterol 1995;90:740-7.
15. 15 Vidrich A, Lee J, James E, Cobb L, et al. Segregation of pANCA antigenic recognition by DNase treatment of neutrophils: ulcerative colitis, type 1 autoimmune hepatitis, and primary sclerosing cholangitis. J Clin Immunol 1995;15:293-9.
16. 16 Toyoda H, Wang SJ, Yang HY, et al. Distinct associations of HLA class II genes with inflammatory bowel disease. Gastroenterology 1993;104:741-8.
17. 17 Yang HY, Rotter JI, Toyoda H, et al. Ulcerative colitis: a genetically heterogeneous disorder defined by genetic (HLA class II) and subclinical (antineutrophil cytoplasmic antibodies) markers. J Clin Invest 1993;92:1080-4.
18. 18 Satsangi J, Landers CJ, Welsh KI, et al. The presence of anti-neutrophil antibodies reflects clinical and genetic heterogeneity within inflammatory bowel disease. Inflamm Bowel Dis 1998;4:18-26.
19. 19 Ruemmele FM, Targan SR, Levy G, et al. Diagnostic accuracy of novel serological assays in pediatric inflammatory bowel disease. Gastroenterology 1998; 115:822-9.
20. 20 Freeman HJ. Atypical perinuclear antineutrophil cytoplasmic antibodies (p-ANCA) in patients with Crohn's disease. Gastroenterology 1998;114:A979.
21. 21 Plevy SE, Landers CJ, Vasiliauskas EA, et al. Alterations in serum immunoglobulin (Ig) G subclasses provide evidence for distinct immune responses in pANCA positive Crohn's disease patients. Gastroenterology 1996;110:A993.
22. 22 Barclay GR, McKenzie H, Pennington J, et al. The effect of dietary yeast on the activity of stable chronic Crohn's disease. Scand J Gastroenterol Suppl 1992;27:196-200.
23. 23 Sendid B, Colombel JF, Jacquinot PM, et al. Specific antibody response to oligomannosidic epitopes in Crohn's disease. Clin Diagn Lab Immunol 1996:3:219-26.
24. 24 McKenzie H, Main J, Pennington CR, et al. Antibody to selected strains of Saccharomyces cerevisiae (baker's and brewer's yeast) and Candida albicans in Crohn's disease. Gut 1990;31:536-8.
25. 25 Darroch CJ, Christmas SE, Barnes RM. In vitro human lymphocyte proliferative responses to a glycoprotein of the yeast Saccharomyces cerevisiae. Immunology 1994;81:247-52.
26. 26 Taylor KD, Li Z, Barry M, et al. Tumor necrosis factor microsatellite haplotype A11B4C1D3E3 is associated with anti-Saccharomyces cerevisiae antibody (ASCA) across clinical forms of inflammatory bowel disease. Gastroenterology 1998;114:A1098.
27. 27 Quinton JF, Sendid B, Reumaux D, et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998;42: 788-91.
28. 28 Duerr RH, Targan SR, Landers CJ, et al. Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1991; 100:1385-91.
29. 29 Targan SR, Landers C, Vidrich A, et al. High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. Gastroenterology 1995;108:1159-66.
30. 30 Saxon A, Shanahan F, Landers C, et al. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol 1990;86:202-10.
31. 31 Giaffer MH, Clark A, Holdsworth CD. Antibodies to Saccharomyces cerevisiae in patients with Crohn's disease and their possible pathogenic importance. Gut 1992;33: 1071-5.
32. 32 Lindberg E, Magnusson K-E, Tysk C, et al. Antibody (IgG, IgA, and IgM) to baker's yeast (Saccharomyces cerevisiae), yeast mannan, gliadin, ovalbumin and betalactoglobulin in monozygotic twins with inflammatory bowel disease. Gut 1992;33:909-13.
33. 33 Elmgreen J, Sorenson H, Berkowicz A. Polymorphism in complement C3 in chronic inflammatory bowel disease. Predominance of the C3F gene in Crohn's disease. Acta Med Scand 1984;2155:375-8.
34. 34 Hesresbach D, Alizadeh M, Bretagne JF, et al. Investigation of the association of major histocompatibility complex genes, including HLA class I, class II and TAP genes, with clinical forms of Crohn's disease. Eur J Immunogenet 1996; 23:141-51.
35. 35 Bouma G, Poen AC, Garcia-Gonzalez MA, et al. HLA-DRB1*03, but not the TNFA-308 promoter gene polymorphism, confers protection against fistulising Crohn's disease. Immunogenetics 1998;47:451-5.
36. 36 Norlén BJ, Krause U, Bergman L. An epidemiological study of Crohn's disease. Scand J Gastroenterol Suppl 1970;5:385-90.
37. 37 Lee FI, Costello FT. The changing incidence of Crohn's disease in Blackpool 1969-1983. Front Gastrointest Res 1986;11:102-13.
38. 38 Halme L, von Smitten K, Husa A. The incidence of Crohn's disease in the Helsinki metropolitan area during 1975-1985. Ann Chir Gynaecol 1989;78:115-19.
39. 39 Fleischer DE, Grimm IS, Friedman LS. Inflammatory bowel disease in older patients. Med Clin North Am 1994;78:1303-19.
40. 40 Puntis J, McNeish AS, Allan RN. Long term prognosis of Crohn's disease with onset in childhood and adolescence. Gut 1984;25:329-36.
41. 41 Cooke WT. Long term prognosis of Crohn's disease with onset in childhood and adolescence. Gut 1984;25:1303-5.
42. 42 Mashako MN, Cezard JP, Navarro J, et al. Crohn's disease lesions in the upper gastrointestinal tract: correlation between clinical, radiological, endoscopic, and histological features in adolescents and children. J Pediatr Gastroenterol Nutr 1989;8:442-6.
43. 43 Lenaerts C, Roy CC, Vaillancourt M, et al. High incidence of upper gastrointestinal tract involvement in children with Crohn's disease. Pediatrics 1989;83:777-81.
44. 44 Polito JM II, Childs B, Mellits ED, et al. Crohn's disease: influence of age at diagnosis on site and clinical type of disease. Gastroenterology 1996;111:580-6.
45. 45 Devlin HB, Datta D, Dellipiani AW. The incidence and prevalence of inflammatory bowel disease in North Tees Health District. World J Surg 1980;4:183-93.
46. 46 Gupta S, Saverymuttu SH, Keshavarzian A, et al. Is the pattern of inflammatory bowel disease different in the elderly? Age Ageing 1985;14:366-70.
47. 47 O'Keefe EA, Wright JP, Froggatt J, et al. Medium-term follow-up of Crohn's disease in Cape Town. S Afr Med J 1989;76:139-41.
48. 48 Whelan G, Farmer RG, Fazio VW, et al. Recurrence after surgery in Crohn's disease: relationship to location of disease (clinical pattern) and surgical indication. Gastroenterology 1985;88:1826-33.
49. 49 Farmer RG, Whelan G, Fazio VW. Long-term follow-up of patients with Crohn's disease: relationship between the clinical pattern and prognosis. Gastroenterology 1985;88: 1818-25.
50. 50 Greenstein AJ, Lachman P, Sachar DB, et al. Perforating and non-perforating indications for repeated operations in Crohn's disease: evidence for two clinical forms. Gut 1988; 29:588-92.
51. s51 Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990;99:956-63.
52. 52 Sachar DB, Andrews HA, Farmer RG, et al. Proposed classification of patient subgroups in Crohn's disease. Gastroenterol Int 1992;5:141-54.
53. 53 Aeberhard P, Berchtold W, Riedtmann HJ, et al. Surgical recurrence of perforating and nonperforating Crohn's disease: a study of 101 surgically treated patients. Dis Colon Rectum 1996;39:80-7.
54. 54 Sachar DB, Subramani K, Mauer K, et al. Patterns of post-operative recurrence in fistulizing and stenotic Crohn's disease: a retrospective cohort study of 71 patients. J Clin Gastroenterol 1996;22:114-16.
55. 55 Monsen U, Bernell O, Johansson C, et al. Prevalence of inflammatory bowel disease among relatives of patients with Crohn's disease. Scand J Gastroenterol Suppl 1991;26: 302-6.
56. 56 Yang H, McElree C, Roth M-P, et al. Familial empirical risks for inflammatory bowel disease: differences between Jews and non-Jews. Gut 1993;34:517-24.
57. 57 Bayless TM, Tokayer AZ, Polito JM II, et al. Crohn's disease: concordance for site and clinical type in affected family members - potential hereditary influences. Gastroenterology 1996;111:573-9.
58. 58 Polito JM II, Rees RC, Childs B, et al. Preliminary evidence for genetic anticipation in Crohn's disease. Lancet 1996; 347:798-800.
59. 59 Satsangi J, Grootscholten C, Holt H, et al. Clinical patterns of familial inflammatory bowel disease. Gut 1996;38:738 41.
60. 60 Peeters M, Nevens H, Baert F, et al. Familial aggregation in Crohn's disease: increased age-adjusted risk and concordance in clinical characteristics. Gastroenterology 1996;111: 597-603.
61. 61 Ettenger RB, Blifeld C, Prince H, et al. The pediatric nephrologist's dilemma: growth after renal transplantation and its interaction with age as a possible immunologic variable. J Pediatr 1987;111:10225.
62. 62 Ettenger RB. Children are different: the challenges of pediatric renal transplantation. Am J Kidney Dis 1992;20:668 72.
63. 63 Yanase Y, Tango T, Okumura K, et al. Lymphocyte subsets identified by monoclonal antibodies in healthy children. Pediatr Res 1986;20:1147-51.
64. 64 Tucker LB, Menon S, Schaller JG, et al. Adult-and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology, and outcome. Br J Rheumatol 1995;34:866-72.
65. 65 Cole GF, Stuart CA. A long perspective on childhood multiple sclerosis. Dev Med Child Neurol 1995;37:661-6.
66. 66 von Mutius E. Progression of allergy and asthma through childhood to adolescence. Thorax 1996;51(suppl 1):S3-6.
67. 67 Host A, Jacobsen HP, Halken S, et al. The natural history of cow's milk protein allergy/intolerance. Eur J Clin Nutr 1995;49(suppl 1):S13-18.